Alcohol and cancer
On 8 July 2025, there will be a Commons debate on alcohol and cancer. The debate will be led by Cat Smith MP. The Library will publish a briefing ahead of the debate.

This briefing provides an overview of the Health Service Commissioner for England (Complaint Handling) Act 2015.
Health Service Commissioner for England (Complaint Handling) Act 2015 (2 MB , PDF)
On 2 July 2014, David Davis presented the Health Service Commissioner for England (Complaint Handling) Bill, having come 19th in the Private Members’ Bill ballot.
The Bill received its Commons Second Reading on 17 October 2014, its Committee stage on 15 January 2015, and its Report Stage and Third Reading on 27 February 2015. In the House of Lords, the Bill received its First Reading on 2 March 2015, Second Reading on 13 March, Committee Stage on 19 March and Third Reading on 25 March 2015. The Bill received Royal Assent and became an Act of Parliament on 26 March 2015.
The Act has two distinct objectives that together seek to improve the handling of complaints by the Health Service Commissioner for England. The Act amends Section 14 of the Health Service Commissioners Act 1993 as follows:
The Act extends to England and Wales only. The changes introduced by the Bill will, however, apply only to the Health Service Commissioner for England and complaints within her remit. The Act comes into force on 26 May – two months after the day on which it was passed.
Health Service Commissioner for England (Complaint Handling) Act 2015 (2 MB , PDF)
On 8 July 2025, there will be a Commons debate on alcohol and cancer. The debate will be led by Cat Smith MP. The Library will publish a briefing ahead of the debate.
The Controlled Drugs (Procedure for Specification) Bill 2024-2025 had its second reading on Friday 7 March 2025. It was considered by a Public Bill Committee on 25 June 2025 and report stage is scheduled for 11 July 2025. This is a private members' bill.
The price of medicines in the UK is influenced by multiple factors, including agreements with the pharmaceutical industry to cap spending on branded medicines.